Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Alberta

$68,000.00

Determining the biological basis for phenotypic sex differences in kappa opioid receptor function

FY 2023-24

Summary
The kappa opioid receptor (KOR) is one of four related opioid receptor proteins in vertebrates. KOR agonists are both analgesic and dysphoric. I have shown previously that a portion of KOR analgesia is due to engagement of dysphoric pathways leading to stress-induced analgesia. Therefore, systemic KOR analgesia is mediated by a convergence of these analgesic and stress pathways. The KOR system is also notable for a prominent sex-difference, where females show significantly less analgesia than males. It is unknown if a similar sexual dichotomy exists in the stress effects of KOR agonists, and how this might impact KOR analgesia. Sexually dimorphic traits can be due to either the influence of gonadal hormones (testosterone or estrogen) or the complement of genes expressed on the X or Y chromosome. Historically, removal of the gonads (testes or ovaries) has been used to examine sex differences. However, the influence of genes expressed on the sex chromosomes cannot be revealed by this approach, because the sex chromosomes are only ever expressed with their appropriate gonad (X with ovaries, Y with testes). To overcome this limitation, I employ two innovative genetic approaches to manipulate the expression of sex chromosome with gonadal hormones. I test the hypothesis that females exhibit lower KOR-mediated analgesia due to differences in the stress response mediated by X chromosome genes. For the first aim, I test the hypothesis that differences in KOR analgesia are due to differences in stress response by using a variety of behavioral tests of pain and anxiety in combination with pharmacological manipulation of the stress response. In the second aim, I will use transgenic mouse models to isolate and assess the contribution of gonadal hormones and sex chromosomes in mediating these sex differences. These models manipulate the expression of X and Y chromosomes with the gonads (i.e: generate XX mice with testes and XY mice with ovaries). This powerful tool allows me to test, simultaneously, the impact of gonadal hormones and sex chromosomes on the observed sex difference. It is now widely accepted that normal and pathological brain function exhibits important yet poorly understood sex differences. This study directly addresses this issue by examining the neurobiological basis for the difference in KOR function between males and females. Insights gleaned from these experiments can be used to illuminate fundamental differences in stress and pain processing between males and females. Not only will this information improve our understanding of basic neurobiology in females, but will improve the development of future therapies for pain and analgesia in both sexes. Finally, this research program will allow me to establish breeding colonies for these genetic models, thus positioning my lab to be a an elite training environment examining the mechanistic basis for sex differences across many phenotypic modalities.
Program
Discovery Grants Program - Individual
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2018-04010
Name nom
Taylor, Anna
Department département
Pharmacology
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2018
Award amount
68000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5501
Research subject group en
Animal biology
Research subject group fr
Neurophysiology
Research subject en
Biologie animale
Research subject fr
Neurophysiologie
Application title
Determining the biological basis for phenotypic sex differences in kappa opioid receptor function
Keyword
analgesia; anxiety; behavioural genetics; dysphoria; kappa opioid receptor; opioid; pharmacology; sex differences; stress
Application summary
The kappa opioid receptor (KOR) is one of four related opioid receptor proteins in vertebrates. KOR agonists are both analgesic and dysphoric. I have shown previously that a portion of KOR analgesia is due to engagement of dysphoric pathways leading to stress-induced analgesia. Therefore, systemic KOR analgesia is mediated by a convergence of these analgesic and stress pathways. The KOR system is also notable for a prominent sex-difference, where females show significantly less analgesia than males. It is unknown if a similar sexual dichotomy exists in the stress effects of KOR agonists, and how this might impact KOR analgesia. Sexually dimorphic traits can be due to either the influence of gonadal hormones (testosterone or estrogen) or the complement of genes expressed on the X or Y chromosome. Historically, removal of the gonads (testes or ovaries) has been used to examine sex differences. However, the influence of genes expressed on the sex chromosomes cannot be revealed by this approach, because the sex chromosomes are only ever expressed with their appropriate gonad (X with ovaries, Y with testes). To overcome this limitation, I employ two innovative genetic approaches to manipulate the expression of sex chromosome with gonadal hormones. I test the hypothesis that females exhibit lower KOR-mediated analgesia due to differences in the stress response mediated by X chromosome genes. For the first aim, I test the hypothesis that differences in KOR analgesia are due to differences in stress response by using a variety of behavioral tests of pain and anxiety in combination with pharmacological manipulation of the stress response. In the second aim, I will use transgenic mouse models to isolate and assess the contribution of gonadal hormones and sex chromosomes in mediating these sex differences. These models manipulate the expression of X and Y chromosomes with the gonads (i.e: generate XX mice with testes and XY mice with ovaries). This powerful tool allows me to test, simultaneously, the impact of gonadal hormones and sex chromosomes on the observed sex difference. It is now widely accepted that normal and pathological brain function exhibits important yet poorly understood sex differences. This study directly addresses this issue by examining the neurobiological basis for the difference in KOR function between males and females. Insights gleaned from these experiments can be used to illuminate fundamental differences in stress and pain processing between males and females. Not only will this information improve our understanding of basic neurobiology in females, but will improve the development of future therapies for pain and analgesia in both sexes. Finally, this research program will allow me to establish breeding colonies for these genetic models, thus positioning my lab to be a an elite training environment examining the mechanistic basis for sex differences across many phenotypic modalities.
University of Alberta - $68,000 Grant (2023-24) | Canada Spends